RxDoctor Payments Data

Vyshali Reddy Loupe, MD

Internal Medicine · Mobile, ALNPI 1659531440

Payments from drug & device makers

$2,224in general payments, 2019–2025

Across 139 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$419
  • AbbVie$269
  • Daiichi Sankyo Inc.$220
  • Amgen$181
  • Lilly USA, LLC$159
  • Bayer$132
  • plus $843 from 21 others

What the payments were for

  • Food & beverage$2,224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,224 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$88,292
Medicare patients
207
Services billed
2,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$283,211
FarxigaDapagliflozin Propanediol80$85,297
EliquisApixaban39$51,655
TrulicityDulaglutide47$45,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$39,648
MounjaroTirzepatide29$35,853
LinzessLinaclotide36$27,351
TradjentaLinagliptin30$26,529
JanuviaSitagliptin Phosphate30$25,412
JardianceEmpagliflozin25$23,532
XareltoRivaroxaban13$21,358
VascepaIcosapent Ethyl26$11,104
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$10,528
Tresiba Flextouch U-100Insulin Degludec15$9,621
Atorvastatin Calcium598$6,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$419$283,211217 claims
AstraZenecaFarxiga$118$85,29780 claims
Lilly USA, LLCTrulicity, Mounjaro$159$81,40076 claims
PfizerEliquis$73$51,65539 claims
Boehringer IngelheimTradjenta, Jardiance$29$50,06155 claims
GSKTrelegy Ellipta$115$39,64838 claims
AbbVieLinzess, Synthroid$269$31,37777 claims
MerckJanuvia$17$25,41230 claims
Johnson & JohnsonXarelto$37$21,35813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →